Abstract: The present invention relates to an integrated system and method for EEG signal acquisition and interpretation, for neonatal seizure detection. The system as per the present invention comprises a control device, an integrated circuit, a wireless communication module, a visual indication means, and a power management module. The control device has a Convolutional Neural Network (CNN) embedded on it, and is programmed to configure the integrated circuit to receive a plurality of channels of EEG data from a plurality of EEG acquisition electrodes, and to amplify and digitize the received EEG data. The integrated circuit is further configured to segment the channels of EEG data to a plurality of sequential epochs of EEG data. The control device is configured to pass the sequential epochs of EEG data through the CNN which is pre-trained to output the probability of a seizure in the EEG data passed through it.

Abstract: The present invention discloses a method and system of providing a real time audification of neonatal EEG signals. The method comprises the steps of: receiving preprocessed neonatal EEG signals; changing a characteristic of the preprocessed signals in a phase vocoder; resampling the output signals from the vocoder to a predetermined audio frequency range; converting the resampled signals into stereo signals; and selecting a plurality of channels from the stereo signals as the output audio signals.

Abstract: The present invention discloses a method and system of providing a real time audification of neonatal EEG signals. The method comprises the steps of: receiving preprocessed neonatal EEG signals; changing a characteristic of the preprocessed signals in a phase vocoder; resampling the output signals from the vocoder to a predetermined audio frequency range; converting the resampled signals into stereo signals; and selecting a plurality of channels from the stereo signals as the output audio signals.

Abstract: A method for screening a distressed neonate for risk of having or developing HIE comprises the steps of assaying a biological sample obtained from the distressed neonate, the mother of the neonate, or from the umbilical cord or placenta, for an abundance of miR-374a in the sample, and comparing the abundance of miR-374a in the sample with a reference abundance of miR-374a, wherein a reduced abundance of miR-374a in the sample compared with the reference abundance of miR-374a is indicative of the distressed neonate being at risk of having or developing HIE. Risk of severe HIE can be determined by assaying a biological sample from the distressed neonate identified as being at risk of HIE for an abundance of a plurality of metabolites including succinate, glycerol, acetone and 3-hydroxybutyrate, providing the sum of glycerol and succinate abundance and the sum of acetone and 3-hydroxybutyrate; and correlating the sums with risk of severe HIE.